Compounders Research Compare

Satellos Bioscience Inc.(MSLE)

Biotechnology · Toronto, ON

$8.09+0.04 (+0.43%)

Delayed quote: Oct 6, 2026, 11:01 AM EDT

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Toronto, ON

18 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Francis Gleeson

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:37:38.690Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:37:38.690Z.

Quote observation: 2026-10-06T15:01:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 10,415,453
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 7,384,128
TTM free cash flow · period ending 2026-06-30: -28,676,071

FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

MSLE EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

MSLE Competitors' EV/FCF Ratio

Satellos Bioscience Inc.

Current

Market Cap

$10.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Caring Brands, Inc.

Market Cap

$10.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lifeward Ltd.

Market Cap

$10.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Polyrizon Ltd.

Market Cap

$10.53M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NeuroOne Medical Technologies Corporation

Market Cap

$10.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Medicus Pharma Ltd. Common Stock

Market Cap

$10.07M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cerenome, Inc.

Market Cap

$10.82M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CytoMed Therapeutics Limited

Market Cap

$10.88M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lisata Therapeutics, Inc.

Market Cap

$10.93M

EV/FCF Ratio

N/A

TTM Avg

5.79x

3Y Avg

5.79x

5Y Avg

5.79x

Ainos, Inc.

Market Cap

$9.80M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Satellos Bioscience Inc. (MSLE)	$10.42M	N/A	N/A	N/A	N/A
Caring Brands, Inc. (CABR)vs ›	$10.36M	N/A	N/A	N/A	N/A
Lifeward Ltd. (LFWD)vs ›	$10.60M	N/A	N/A	N/A	N/A
Polyrizon Ltd. (PLRZ)vs ›	$10.53M	N/A	N/A	N/A	N/A
NeuroOne Medical Technologies Corporation (NMTC)vs ›	$10.18M	N/A	N/A	N/A	N/A
Medicus Pharma Ltd. Common Stock (MDCX)vs ›	$10.07M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$10.82M	N/A	N/A	N/A	N/A
CytoMed Therapeutics Limited (GDTC)vs ›	$10.88M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$10.93M	N/A	5.79x	5.79x	5.79x
Ainos, Inc. (AIMD)vs ›	$9.80M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics